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ABSTRACT 
 
 
 
 ii 
The underlying biological event(s) implicated in the increased expression of nestin in 
cardiac resident neural stem cells (NSC) following myocardial infarction (MI) remain 
unknown. Past studies have shown  that dexamethasone treatment, a synthetic 
glucocorticoid with potent anti-inflammatory properties, abolished the upregulation of 
nestin in the non-infacted left ventricle (NILV) following MI. This suggests an association 
with the inflammatory response. The present study tested the hypothesis that the 
inflammatory cytokine interleukin-1! (IL-1!) can influence the neural stem cell phenotype. 
A secondary goal of the study was to assess impact of IL-1! signalling inhibition on 
cardiac function and wound healing following MI. Following complete coronary artery 
ligation of the adult male rat heart, left ventricular contractile dysfunction was associated 
with the upregulation of the pro-apoptotic protein bax, the anti-apoptotic protein Bcl-2 and 
nestin in the non-infarcted myocardium. Xoma 052 (1 mg/kg), an IgG antibody directed 
against IL-1!, was administred 24 hrs after ischemic injury and subsequently injected 2x 
over a period of 21 days. Treatment did not alter infarct size or improve left ventricular 
contractility. In addition, it failed to abolish the increased expression of nestin and Bcl-2, 
and modestly reduced bax protein levels. To directly assess the relationship between 
inflammation and the expression of nestin in the absence of an ischemic insult, adult male 
rats were injected with lipopolysaccharide (LPS) (10mg/kg;18 hrs). In the heart of LPS-
treated rats, IL-1! mRNA levels were significantly increased and associated with elevated 
nestin protein expression. The pre-treatment with Xoma 052  (10mg/kg) abolished the 
increased expression of nestin in the heart of LPS-treated rats. These data indicate that 
neural stem cells may represent a target for IL-1!. However, futher investigation is required  
to elucidate the role of IL-1! on NSC following MI.
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RÉSUMÉ 
 v 
Le mécanisme biologique responsable pour l’augmentation de l’expression de la 
protéine nestin dans les cellules souches neurales (CSN) du cœur après un infarctus du 
myocarde (IM) demeure inconnu. Des études antérieures ont démontré que le traitement au 
dexamethasone, un glucocorticoïde aux propriétés anti-inflammatoires, abolit la régulation 
positive de nestin après un IM. Ceci suggère un lien avec la réponse inflammatoire. Nous 
avons vérifié dans cette étude l’hypothèse que la cytokine inflammatoire interleukin-1 ! 
(IL-1!) peut modifier le phénotype de cellules souches neurales. Le deuxième objectif de 
l’étude fut d’établir l’impact, suivant un IM, de l’inhibition de la signalisation de IL-1! sur 
la fonction et la guérison cardiaque. Suite à une ligature complète de l’artère coronaire du 
rat mâle, le dysfonctionnement contractile du ventricule gauche fut associé à une régulation 
positive de la protéine nestin dans le myocarde non-infarci. Le traitement avec Xoma 052 
(1 mg/kg), un anticorps anti-IL-1!, 24h, 7 et 14 jours après un évènement ischémique, eu 
aucun effet sur la taille de l’infarctus ou la contractilité du ventricule gauche. De plus, le 
traitement avec Xoma 052 après un IM n’a pu supprimer l’augmentation de l’expression de 
nestin et Bcl-2 malgré une réduction modeste du niveau de la protéine Bax.  Pour 
déterminer directement le rôle de la réponse inflammatoire en l’absence d’ischémie, nous 
avons injecté des rats mâles avec du LPS (10mg/kg, 18hrs). Dans le coeur du rat-LPS, nous 
avons noté une augmentation significative du niveau d’ARNm de IL-1! et de l’expression 
de la protéine nestin. Le prétraitement avec 10mg/kg de Xoma 052 a aboli l’augmentation 
de l’expression de nestin dans le coeur des rats-LPS. Ces observations indiquent que les 
cellules souches neurales pourraient représenter une cible potentielle de l’IL-1!.  
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1. Myocardial Infarction 
 
A myocardial infarction (MI) is caused by an occlusion of one or more coronary arteries 
that supply oxygenated blood to the myocardium. The blockage caused by the rupture of 
atherosclerotic plaque blocks the flow of blood leading to ischemia. The resulting state of 
hypoxia experienced by the ischemic tissue leads to the damage and death of the affected 
cardiomyocyte population. 
  
 
 
Figure1. Occlusion of coronary artery causing Myocardial infarction  
Source: http://www.medicinenet.com/heart_attack/article.htm 
 
The resulting damage to affected tissue initiates a cascade of local physiological and 
cellular events that significantly compromise the function of the remaining viable 
myocardium. Decreased cardiac function characterized by a drop in mean arterial blood 
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pressure and LV dp/dt indices lead to hypertrophy of left ventricle. The inflammatory 
response initiated by the release of pro-inflammatory cytokines and chemokines 
contributes to would healing via scar formation.  
 
 
2 Left Ventricular Remodeling Post-MI 
 
2.1 Early Remodeling 
 
Following myocardial infarction, the ventricle undergoes a plethora of physiological 
changes including dilation,  hypertrophy and scar thinning. Globally, these changes are 
referred to as ventricular remodeling and are the primary factors associated with 
increased mortality and morbidity in patients having suffered from an ischemic insult.  
In the early stages of ventricular remodeling, the cardiac myocytes of the ischemic 
tissue undergo necrosis and the surrounding collagen network begins to degrade due to 
changes in the balance of matrix metalloproteinase to tissue inhibitor of 
metalloproteinase (MMP/TIMP) (1). Three to four days following infarction, the infarct 
region is invaded by phagocytic cells including macrophages and neutrophils to remove 
the necrotic tissue.  About 5 days after the ischemic insult, an expansion of the infarct 
region is observed. This expansion has been described as the acute dilation and thinning 
of the infarct area which leads to a dilation of the ventricular cavity. The preceding 
degradation of the collagen matrix decreases the structural support for cardiac myocytes. 
The side-to-side slippage of the cardiac myocytes is the primary reason for the expansion 
of the infarct area(2). The ensuing dilation of the ventricular cavity leads to decreased 
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contractile force, a decrease in the ejection fraction of the ventricle and an overall 
decrease in cardiac function(3).  
 
"!
Figure 2. Dilation of the left ventricle following myocardial infarction. 
Source: http://stemcells.nih.gov/info/2006report/2006Chapter6.htm 
 
Subsequently, the necrotic tissue is reabsorbed by the invading phagocytic cells and 
migrating myofibroblasts deposit large amounts of collagen fibers which stabilizes the 
infarct area(4). 
 
2.2 Late Stage Remodeling : Cardiac Hypertrophy 
Once a sufficient amount of collagen has accumulated, a scar forms and the infarct ceases 
to expand when the distending forces are balanced by the tensile strength of the scar(5). 
The resulting increase in wall stress caused by the expansion of the ventricular cavity 
provides the physiological stimulus to initiate a cascade of signaling events(6)  leading to 
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cardiac hypertrophy. This event represents an adaptive response of the infarcted 
myocardium which serves to attenuate dilation and stabilize cardiac function(5).  Indeed, 
microscopic observations have determined that myocyte volume can increase up to 
70%(7). Myocyte hypertrophy is induced by mechanical stress and various other stimuli 
such the renin-angiotensin system and paracrine/autocrine signals(5) induced to 
compensate for the decrease in cardiac output.  
 
2.3 The Apoptotic Response following Myocardial infarction 
 
Following myocardial infarction, a substantial number of cardiomyocytes in and 
around the ischemic zone are lost. The oxygen deprivation resulting from the blockage in 
arterial blood flow directly causes the death of many cardiomyocytes via necrosis. 
However, a substancial number also succumb to apoptosis. Apoptosis is an evolutionary 
conserved process of programmed cell death crucial to the normal functioning of 
multicellular organisms. The pathways that mediate apoptosis are more than one billion 
years old and essential to many fundamental biological processes such as proliferation, 
differentiation, death, inflammation, and immunity(8). The apoptotic response can be 
triggered in cardiac myocytes by a variety of stimuli including hypoxia, especially after 
reperfusion, oxidative stress, acidosis and glucose deprivation(8). It is therefore not 
surprising that the dammage resulting from a coronary artery occlusion  can trigger a 
large apoptotic response in the heart. Apoptosis seems to occur in cells both close and 
distant to the necrotic region. However, the response seems to be at its pinnacle in the 
peri-infarct region, with one study reporting apoptotic features in 12% of cardiac 
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myocyte nuclei(9). Compared to necrosis, the apoptotic response occurs in a planned and 
organized fashion, which makes it an attractive therapeutic target to attenuate damage to 
the myocardium and consequently cardiac function following an ischemic event. 
The apoptotic pathway is in part regulated by the action of proteins belonging to 
the Bcl-2 family, initially isolated from a gene encoded in B-cell lymphoma. A plethora 
of proteins belonging to this family were identified and classified into three groups based 
on their general function(10). Group I members, which include Bcl-2 protein itself, all 
have anti-apoptotic properties. An increase in their expression should reduce the 
apoptotic response. Members of group II, which include Bax and Bak, are death agonists 
with pro-apoptotic properties. Their increased expression promotes cell death by 
facilitating the insertion of proteins which disrupt the integrity of the mitochondrial 
membrane(10). Group III contains proteins that bind and regulate the anti-apoptotic Bcl-2 
proteins. In healthy cells, they are phosphorylated and sequestered in the cytoplasm by an 
adapter protein.  
The apoptotic pathway can be separated into two distinct pathways: the extrinsic 
pathway and the intrinsic pathway. The former activates cell death via a specific set of 
death signals while the later does so via a plethora of extracellular  (eg. radiation, trophic 
factors, drugs and physical stresses) and intracellular stresses (eg. DNA damage, 
improper protein folding). The intrinsic pathway, which involves proteins from the Bcl-2 
gene family, most notably Bax, leads to cell death by the disruption of mitochondrial 
function caused by the permeabilization of the outer membrane which in turn release and 
activates a variety of pro-apoptotic proteins(10). Under normal circumstances, the pro-
apoptotic protein Bax is confined in an inactive state to the cytosol, anchored via its C-
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terminus. Through a mechanism that still remains unclear, apoptotic stimuli cause a 
conformational change in the Bax C-terminus, liberating it from its anchor and leading to 
its insertion into the outer mitochondrial membrane. This leads to its permeablization 
either by compromising the integrity of the lipid bilayer or alternatively through the 
formation of Bax containing homooligomeric pores(11). Indeed, it has been reported that 
isolated fibroblasts from transgenic mice lacking both Bax and Bak are highly resistant to 
apoptosis via the activation of the intrinsic pathway(12). Once the outer mitochondrial 
membrane has been compromised, many soluble pro-apoptotic proteins are released from 
the intermembrane space. The most significant of these proteins is cytochrome C, which 
upon release from the mitochondria, initiates the assembly of the apoptosome and the 
activation of the caspase cascades which will ultimately lead to the death of the cell in 
question(13).  
 
Contrary to Bax, the anti-apoptotic protein Bcl-2 is localized at the outer 
mitochondrial membrane. Once again, the exact mechanism describing how the anti-
apoptotic Bcl-2 proteins prevent cytochrome c release and cell death remains a matter of 
much debate. It has been previously hypothesized that the ratio between pro and anti-
apoptotic proteins ultimately decides the fate of the cell(14). However, more recent 
observations  suggest that these proteins may excerpt their effect independently of each 
other(15).  
 
 
Certain genetic approaches using transgenic mice which restrict the induction of 
the caspase-8 allele(16), a protein heavily involved in the apoptotic and necrotic 
 8 
pathways, have shown that inhibition of myocyte apoptosis significantly reduces infarct 
size by up 70%(17). By contrast, pharmacological approaches have yielded much less 
consistent results. However, certain approaches utilising caspace inhibitors have shown a 
21-52% decrease in infarct size(8). These data indicate the possibility of substantial 
therapeutic benefits by modulating the apoptotic response following myocardial 
infarction. 
 
 
 
3. Nestin and Nestin(+) Cells in the Heart 
 
 
Nestin is a 240 kDa type IV intermediate filament protein implicated in the 
plasticity, differentiation and proliferation of CNS-derived neural stem/progenitor cells.   
Nestin expression in the neonatal rat heart is significantly more pronounced than that of 
the adult rat heart. It would seem that postnatal growth of the rat heart is associated with a 
downregulation of the intermediate filament protein. A similar observation was reported 
in skeletal muscle and aortic vascular smooth muscle where nestin was expressed during 
embryogenesis but disappeared in the adult rat ((18), (19)). These observations support 
the notion that nestin expression is implicated in the proliferation of progenitor cells. By 
isolating ventricular cells from neonatal rat pups, it was shown that ventricular fibroblasts 
exhibit overexpression of the intermediate filament whereas ventricular myocytes showed 
little to no nestin expression(20). Furthermore, it was reported that although nestin 
expression is low or absent from adult cardiac myocytes, following an ischemic event, 
nestin (+) myocyte-like cells are observed in proximity to the injured tissue and high 
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nestin expression is observed in the endothelial lining of small caliber blood 
vessels(21),(22). 
 
Recent work from Dr. Calderone and colleagues has unexpectedly identified a 
resident population of nestin (+) neural stem cells in the rodent and human heart(21) 
(figure 3).  
 
Figure 3. Nestin Expressing Cell   Nestin (red) expressing cell isolated from rat atria. The 
Nuclei were stained with the fluorescent marker to-pro3 (blue). El-Helou et al. 2008 
 
These cells are intercaleted between cardiac myocytes in the normal rat heart. 
They are characterized by a small cell body and numerous processes making them 
morphologically different from nestin (+) scar myofibroblasts(22). They were found to 
express the RNA binding protein Musashi-1, which is implicated in maintaing the cell’s 
capacity for self renewal, form neurospheres in vitro in the presence of EGF and bFGF 
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and differentiate to a neural phenotype in vitro characterized by the de-novo synthesis of 
neurofilament M.  
 
Further work by Dr. Calderone and colleagues(21),(23) showed that the viable 
myocardium of the infarcted human heart also contained a subpopulation of nestin (+) 
cells intercalated between cardiac myocytes. These cells were again detected in the peri-
infarct/infarct region of the infarcted human heart. In addition, these cells displayed a 
small cell body with numerous processes bearing a strong morphological resemblence to 
the nestin (+) cells identified in the rodent heart. These observations were confirmed by 
the work of Mokry and colleagues (2008). 
 
The gene expression of this novel cardiac neural stem cell population provides 
some indirect evidence for its neural crest origin. The expression of the neural crest stem 
cell-associated genes sox9, snail and slug were detected primary passage scar-derived 
cells isolated from infarcted rat heart and the left ventricle of the normal rat heart (24). To 
determine the neural crest origin of the cell population, a transgenic mouse was used with 
the neural crest specific promoter Wnt1 driving Cre recombinase expression to activate 
an EGFP reporter gene. In neonatal transgenic mice, an EGFP signal was observed in a 
plethora of nestin expressing cells in the heart giving strong support to the theory that the 
nestin (+) cell population identified in the rat and human hearts are of neural crest origin 
(21). 
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Work from our lab and others(25) has shown that following myocardial infarction, 
nestin (+) cardiac neural stem cells migrate to the infarct region and participate in wound 
healing. Indeed, nestin (+) cardiac neural stem cells were capable of differentiating to 
vascular cells leading to de novo blood vessel formation in the infarct region(26). The 
latter findings were obtained following the isolation and injection of scar-derived 
neurosphere forming nestin (+) neural stem cells into the peri-infarct/infarct region of the 
infarcted rat heart. These cells were individually labelled with the fluorescent cell tracker 
CM-DiI and injected into the heart of 3 day post MI rats. 7 days after injection, they were 
observed exclusively in the scar region. Interestingly, in addition to undifferentiated CM-
DiI labelled nestin+ cells, a subpopulation of CM-DiI labeled cells had differentiated to 
an endothelial and vascular smooth muscle phenotype, characterized by co-staining with 
eNOS and desmin respectively. This differentiation was followed by the de novo 
synthesis of CM-DiI blood vessels in the infarcted region. These observations would 
support the hypothesis that nestin(+) cardiac neural stem cells can participate in the 
angiogenic response following injury to the myocardium. Following an ischemic insult, 
the expression of the intermediate filament protein nestin is upregulated in both the non-
infarcted left ventricle and the scar region. The former would suggest that the number of 
cardiac neural stem cells increases following damage to the myocardium.  
Analogous results were reported by Tomita et. al (2005) showing a subpopulation 
of cardiac resident nestin(+) cells  were capable of differentiating to neuronal, glial and 
vascular phenotypes. A subpopulation of these  cardiac resident nestin(+) cells were plated 
in vitro and unexpectedly expressed markers associated with a cardiomyocyte-like 
phenotype. More specifically, after 7 days in culture, several cardiac specific genes were 
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detected, most notably ANP and Cav1.2. After 14 days, these cells began to beat 
spontaneously. Furthermore, using P0-Cre recombinase/Floxed-EGFP double transgenic 
mice, Tomita et al. (2005) were able to establish that neural crest-derived cells are able to 
migrate into the myocardium and remained there having the capacity to differentiate into 
various types of cells(27). It would seem that this subpopulation of cells remains dormant 
in the heart until a change is initiated by environmental stimuli. Consistent with the latter 
findings, work from Dr. Calderone and colleagues identified nestin (+) myocyte-like cells 
exclusively in the peri-infarct/infarct region of the ischemically damaged heart (figure 4). 
Nestin (+) myocyte-like cells were also detected in the infarcted human and mouse heart 
whereas these cells were absent in the normal myocardium(21). 
= 
Figure 4. Nestin staining in myocyte-like cell. In the peri-infarct region of a 1-week 
post-MI patient, nestin staining was observed in certain cells exhibiting a cardiac myocyte-like phenotype 
(highlighted in box) and not limited to cells with a small cell body and processes (indicated by arrow). 
Nuclei were labelled with the fluorescent marker to-pro3 (blue). El-Helou et al. 2008 
 
 
Phenotypically, these immature cells were characterized by co-staining with the 
intermediate filament protein desmin, an association with an aberrant pattern of 
connexin-43 staining, as the gap junctional protein was absent and/or internalized. It 
 13 
remains presently unknown if nestin (+) myocyte-like cells are derived from 
undifferentiated cardiac resident nestin (+) neural progenitor/stem cells 
 
3.1 Myofibroblasts  
Myofibroblasts are a entirely different class of nestin expressing cells. They 
differentiate from fibroblasts who have migrated to the infarct region following ischemic 
injury. These myofibroblasts, characterized by the expression of "-smooth muscle actin, 
play a crucial role in wound healing following myocardial injury(2). They primarily 
secrete the extracellular matrix proteins collagen I and III which form the basis of the 
structural support in the scar required to prevent cardiac myocyte slippage and left 
ventricular dilation. Consequently, one can determine the effect of a drug on scar 
formation by comparing the mRNA transcript levels of various  collagen proteins. A 
decrease in collagen trancription in drug treated groups compared to control groups 
would be indicative of decreased collagen secretion by myofibroblasts and consequently 
impaired scar formation and wound healing.  Interestingly, it has been observed that 
nestin is only transiently expressed in highly proliferating embryonic and neonatal 
fibroblast and is thereafter lost in adult fibroblasts(28). By contrast, following an 
ischemic insult, myofibroblasts re-express the intermediate filament protein nestin. This 
may prove to be an adaptive response to accelerate the healing process by augmenting 
cellular proliferation.   
 
Understanding the mechanism implicated in the upregulation of nestin is crucial 
to unraveling the biological control of cardiac neural stem cells following myocardial 
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infarction and the first step to elucidating the environmental factors responsible for their 
differentiation to the described cellular phenotypes.  
 
4. Immune Response to MI 
 
4.1 Overview 
Ischemia following myocardial infarction causes a decrease in the oxygen 
availability to cardiac myocytes. In the absence of oxygen, a decrease in oxidative 
phosphorylation is accompanied by a decrease in ATP, cell swelling, an  accumulation of 
lactic acid and glycogen depletion(29). 20-40 minutes after coronary artery occlusion, 
irreversible damage occurs in the myocytes ultimately leading to cell death 
predominantly via coagulation necrosis and apoptosis(30). Factors released from necrotic 
tissue (ex: HMGB18, cardiac myosin 7), termed “danger signals” initiate an innate 
immune response which ultimately activates the NF-kB signalling pathway. NF-kB 
signalling then increases the expression of many key cytokines, chemokines and adhesion 
molecules responsible for the inflammatory response observed in the heart following 
myocardial infarction. 
Our current understanding is that the primary receptor involved in the activation 
of the immune system is toll-like receptor 4 (TLR4). Indeed, TLR4 is expressed in the 
rodent heart and it was found to be significantly induced in myocardiopathy samples(31). 
Furthermore, TLR4-/- mice have decreased infarct size and inflammation and attenuated 
adverse remodelling following coronary artery ligation(32). This would seem to indicate 
that TLR4 is a key component of the innate immune response in the heart following 
myocardial infarction.  
 15 
4.2 The Role of IL-1! 
 
Following acute myocardial infarction, ischemic endothelial cells and 
cardiomyocytes release the pro-inflammatory cytokine IL-1!. Its release initiates the 
inflammatory cascade by stimulating and potentiating the release of other inflammatory 
cytokines such as IL-6, IL-8, MCP-1 and TNF-". In addition, IL-1!  is subject to positive 
feedback as the initial release of IL-1! by the ischemic tissue promotes the recruitment of 
leukocytes into the damaged area, which in turn release IL-1!  themselves(33). Though 
IL-1! is associated with the healing of the infarct area, it also contributes to 
cardiomyocyte apoptosis either directly or in conjunction with the action of TNF-" or 
INF-# via the activation of the  Bak and Bcl-xL pathways(34). 
The IL-1! signalling mechanism is highly regulated and highly complex. The 
current understanding of the signalling mechanism suggests that in order to initiate a 
downstream signal, IL-1! must bind the type 1 cell surface IL-1 receptor which then 
forms a complex with its co-receptor: the IL-1 receptor associated protein. The IL-1 
receptor associated protein must bind the signalling complex to couple ligand binding 
with downstream activation (figure 5). 
.  
 
 
 
 
 
 
Figure 5: Conceptual Diagram of 
the IL-1 Receptor complex (from Xoma) 
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In addition, there exists several forms of negative regulation controlling IL-1! signalling. 
The binding of the IL-1R1 by an IL-1! homologue,  the IL-1 receptor antagonist 
molecule inhibits IL-1! signalling. Secondly, there exists a decoy receptor which 
neutralizes circulating IL-1!, the type II IL-1 receptor(35). It has been shown that 
treatment with an anti-IL-1R2 antibody increases the response to IL-1!(36).  And finally, 
contrary to the membrane bound form of the receptor, the soluble form of the IL-1R1 can 
serve as a trap to inhibit IL-1! signalling. Very little receptor occupancy is required in 
order to initiate a biological response to IL-1!. Studies have shown that as little as 4% 
receptor occupancy is required.  
 
Figure 6: Intracellular signalling targets of IL-1R1 and downstream effects(37) 
It has been suggested that the association of the two cytoplasmic domains for both 
the IL-1RacP and the IL-1R1 is a necessary event for the activation of IL-1 receptor 
associated kinases (IRAK),  stress activated protein kinases (SAP kinases)(38) and a TNF 
receptor associated factor (TRAF6). IL-1R1 activates the adapter protein MyD88 via a 
homophilic protein-protein interaction between the cytoplasmic domain of the receptor 
and the TIR domain of MyD88(39). Using a negative construct, Medzhitov et al. showed 
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that MyD88 interacted with and activated the downstream targets IRAK and possibly 
TRAF6. Following the interaction between MyD88 and IRAK, the later becomes 
phosphorylated and interacts with TRAF6. Interacting with TRAF6, Interferon-gamma 
inducing factor (IGIF) would then induce the action of Nuclear factor kappa-beta, a 
transcription factor involved in the transcription of other pro-inflammatory genes.  
 
 
5. Pharmacological Agents used in Study 
 
 
5.1 Lipopolysaccharide (LPS) 
 
 
LPS is a bacterial endotoxin found on the outer cell membrane of most gram negative 
bacterial pathogens such as Escherichia Coli (E. Coli). The binding of LPS to the toll like 
receptor 4 initiates an immune reaction and, with a large enough dose, initiates a massive 
inflammatory response.  
 
Lipid A is a glycosamine-based phospholipid that makes up the hydrophobic anchor of 
the LPS molecule(36) (figure 7). The general structure for Lipid A synthesized by many 
different pathogens is generally conserved. This leads to their recognition by the ancient 
immune receptors Toll-like receptors (TLR). In 1998, Poltorak et al. identified the TLR4, 
a membrane spanning receptor, distantly related to the IL-1R, which recognizes the 
endotoxin. Being related to the IL-1R, it associates with many of the same signalling 
proteins including MyD88 and IRAK.  This leads to the activation NF-kappa beta, p38 
and  AP-1 (adaptor protein 1) genes which will upregulate the transcription of pro-
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inflammatory cytokines such as IL-1, IL-6 and TNF-". The inflammatory response is 
extreme and can lead to septic shock and eventually death(40). 
 
 
    
 
Figure 7: Structure of the LPS molecule (author: Mike Jones) 
Lipid A in yellow at the bottom of the figure is sythesized by many different pathogens 
and is highly conserved.  
 
 
 
5.2 Xoma 052 (Gevokizumab) 
 
Xoma 052 is a novel regulator of IL-1! signalling. It is a IgG2-kappa humanized 
antibody with a strong affinity and specificity for IL-1 !. It blocks ligand binding with its 
receptor IL-1R1 thereby preventing IL-1 ! signalling(figure 8). The half maximal 
inhibitory concentration (IC50) of the antibody is under 10 picomolars indicating a high 
potency. 
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Fig 8 (24). Graph depicting variation in IL-1! signalling in the presence of the Xoma 
052 antibody. The ability of Xoma 052 to inhibit IL-1! signalling was assessed by 
measuring the levels of IL-6, an inflammatory cytokines that is released in response to 
IL-1!. In a study by Roell et al. (35), it was determined that treatment with the antibody 
completely blocked IL-6 release in a concentration dependant manner.  
 
The drug offers many advantages compared to other IL-1! inhibitors. Firstly, it 
has a relatively long circulatory half life, around 23 days. This would translate to more 
convenient dosage administration for future patients. A monthly injection may be 
adequate. By comparison, Anakinra, a recombinant IL-1 Receptor antagonist currently 
used in the treatment of rheumatoid arthritis, has a half life of 4-6 hours. Rinolacept, an 
IL-1 trap used in the treatment of Cryopyrin-associated periodic syndromes (CAPS), has 
a circulatory half life of 8.6 days. Secondly, past studies have suggested that the 
mechanism of action of the antibody is more effective than other methods at inhibiting 
IL-1 signaling. Only 4% receptor occupancy is required for full signalling activity. 
Targeting the ligand is therefore a much more effective strategy than attempting to block 
the receptor.  
In 2011, study by Bhaskar et al. (41) reported that Xoma 052 inhibited 
macrophage-induced secretion of several key atherogenic cytokines from endothelial 
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cells and smooth muscle cells. The cytokines which were reduced, IL-6, IL-8, MCP-1 
and TNF-alpha, are all known to be regulated by IL-1! signalling. Furthermore, it was 
also shown that the expression of certain MMPs was reduced. This gives further evidence 
to the effectiveness of the drug because it has been shown that IL-1! increases the levels 
of MMP-9 and MMP-3. Xoma 052 is an exciting new molecule which fits the criteria 
required to test our objectives.  
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Past work from Dr. Calderone and colleagues has identified a resident population 
of nestin (+) neural stem cells in the heart. It has been shown that the expression of nestin 
is upregulated in the both the scar and non-infarcted left ventricle of the infarcted rodent 
heart. The primary objective of this study was to elucidate the stimuli (ex: signaling 
protein) implicated in the upregulation of nestin following MI.  
Our data has shown that treatment with dexamethosone, a synthetic glucocorticoid 
with potent anti-inflammatory and immunosupressant properties, blocks the upregulation 
of nestin following MI. Though a direct effect of dexamethasone itself cannot be 
excluded, this data would suggest that the inflammatory response plays a role in the 
upregulation of nestin following myocardial infarction. Since IL-1! is a primary mediator 
of the inflammatory response, this provided an opportunity to examine the effect of the 
inflammatory response on the upregulation of nestin. To accomplish this goal, we 
administered the novel antibody Xoma 052 to block IL-1! signalling.  
   Furthermore,  scar formation and healing is an essential process to repair the 
damaged tissue following myocardial infarction. It involves a highly coordinated 
physiological process intiated by inflammatory response, collagen deposition by 
myofibroblasts to replace necrotic tissue and ventricular remodelling to compensate for 
decreased cardiac function. Though necessary, these processes also have a negative 
impact on heart function which ultimately affects the survival and quality of life of infarct 
survivors. The secondary objective of this study was to assess the role of the 
inflammatory response, primarily the role of the pro-inflammatory cytokine IL-1! on 
cardiac function and scar formation following MI.  
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Materials & Methods  
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MI Rat Model and Hemodynamic Measurements 
 
In this model, Male Sprague Dawley rats  (Charles River) weighing about 300g  
were placed under anaesthesia using 2.5% isoflurane, 2L/min Oxygen followed by 
intubation to maintain respiration during surgery. An incision was made in the 4th 
intercostals space followed by the cutting of the pericardium. A myocardial infarction 
was created by ligating the left coronary artery. The ribs were brought together with 
sutures and the wound closed with clips. ECG measurements are taken to monitor the 
survival of the animal. To alleviate suffering in the animal, a dose of buprenorphine was 
administered following surgery.   
 
At 1, 8 and 15 days post MI, a subcutaneous injection of the XOMA 052 drug at a dose 
of 0.1, 1 or 10mg/kg or an IgG vehicle was administered.  
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22 days after MI, the rats were anesthetised with a 1:1 mixture of ketamine (50mg/ml) 
and xylazine (10mg/ml). The intramuscular injection was administered at a dose of 
0.01ml/kg. Lead electrodes were inserted into the upper right and both lower legs to 
measure and establish Einthoven`s triangle. This enabled the electrocardiogram to view 
the electrical activity of the heart. The EMKA 1.8.11..12 program also provided a 
measure of the heart rate by the addition of the QR or measure the systolic pressure 
curves.  
 
Following an incision in the neck of the animal, the right carotid artery was located and 
and Millar catheter (2F) was inserted and threaded to the left ventricle to record carotid 
and ventricular pressures. The Millar catheter is removed and a fluid filled catheter was 
inserted into right juglar vein and threaded to the right ventricle to measure pressure. The 
method also calculated the rate of contraction (dp/dT), based on the steepest point of the 
descending pressure curve. The diastolic pressure is represented by the smallest pressure 
reading of the pressure curve. The end-diastolic pressure is the point when the slope 
begins to rise and the systolic pressure is the highest peak point of the curve.  
 
Before sacrifice, approximately 6ml of blood was drawn from the inferior vena cava and 
stored on ice. This is followed by an incision in the lower abdomen, the cutting of the 
diaphragm and the excision of the animals heart. Following excision, the heart is weighed 
and stored in either 2-methylbutane for immunofluorescence or cut up and frozen in 
liquid nitrogen for use in molecular biology experiments. The use and care of laboratory 
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animals was according to the Canadian Council for Animal Care and all animal studies 
were approved by the Animal Care Ethics Committee of the Montreal Heart Institute.   
 
LPS model  
 
In this model, Male Sprague Dawley rats  (Charles River) weighing about 300g  were 
injected subcutaneously with the Xoma 052 antibody (1mg/kg, 10mg/kg). 8 hours 
following the administration of the drug, the animals were injected IP with 10mg/kg LPS 
from Escherichia Coli 055:B5 purified by phenol (Sigma L2880; dissolved in 0.8% 
Saline). Approximately 15 hours following LPS injection, the rats were anesthetised with 
a 1:1 mixture of ketamine (50mg/ml) and xylazine (10mg/ml). The intramuscular 
injection was administered at a dose of 0.01ml/kg. Hemodynamic measurements were 
taken as described above.  The use and care of laboratory animals was according to the 
Canadian Council for Animal Care and all animal studies were approved by the Animal 
Care Ethics Committee of the Montreal Heart Institute.  
 
Western Blot to measure protein expression  
Protein Extraction 
 
 The cardiac tissue were lysed using a buffer containing 150mM NaCl, 10mM Tris 
(pH 7.5), 1mM EDTA (pH 7.0), 1mM EGTA (pH 9.0), 50mM NaF, 1% Triton-X, 0.5% 
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Igepal CA-360, 1mM ortho-vanadate, 1 µg/mL Leupetin (1mg/mL DMSO), 1 µg/mL 
Aprotinin (1mg/mL) and 500µM Phenyl methyl sulfonyl fluoride, with the final pH 7.4. 
The tissue sample was placed in a 50mL tube containing 3mL of the lysis buffer. The 
tissue was grinded using the Polytron at a speed of 20 500 rpm and the samples settled on 
ice for 1 hour. The samples were then centrifuged at 10 000 rpm for 10 minutes at 4˚C. 
The supernatant was transferred and stored at -80˚C. The protein concentration was 
assessed using the Bradford assay technique.  
 
Mini-Western Blot 
The results for the Bradford Protein Assay were used to calculate and load a 30 µg 
protein sample. The samples were directly mixed with SBJ 2X for a 15µL loading 
volume. The SBJ contained 1 M Tris (pH 6.8), 30% glycerol, 6% SDS, 15% !-
mercaptoethanol and bromophenol blue. Prior to loading, the samples were heated at 
70˚C for 5 minutes to denature the proteins. The denatured samples were loaded into the 
wells of a 8.75-12.5% SDS-polyacrylamide gel with a width of 1mM and subjected to 
electrophoresis at 200V for 45-60 minutes. The protein was subsequently transferred at 
100V for 90-105 minutes to a PVDF membrane. Immunoblotting was performed using 
5% skim milk dissolved in PBS-Tween followed by several washings with PBS-T. The 
primary antibody was added the 5% milk mixture and incubated overnight at 4˚C with the 
membrane in a bottle on a rotating rack. The antibodies used include mouse monoclonal 
anti-nestin (1:500; Millipore), rabbit monoclonal anti-iNOS (1:1000 Assay Design), 
rabbit anti-iNOS (1:1000; Enzo) mouse monoclonal anti-Bcl-2 (1:200; BD Transduction 
Laboratories), Mouse monoclonal anti-Bax (1:200; Santa Cruz Biotech), Rabbit 
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monoclonal anti-GAP43 (1:500; Millipore), rabbit monoclonal anti-eNOS ( 1:500; Assay 
Design). Following primary antibody incubation and washing with PBS-T, goat anti-
mouse or goat anti-rabbit conjugated to horseradish peroxidase (1:20 000) was added and 
visualization of the bands were detected by autoradiography utilizing the ECL detection 
kit (0.125ml of substrate added/cm% of membrane area).   
 
Molecular Biology Techniques 
Real-Time Polymerase Chain Reaction (RT PCR) 
 
 Total RNA was isolated from the control and treated samples of Sham, LPS 
and/or Xoma 052 treated adult rat hearts by a modification of the guanidine 
isothiocyanate-phenol-chloroform method. A cDNA library was generated by incubating 
10µl (0.2µg/µl) total RNA (each sample). M-MLV reverse transciptase (800 U, Applied 
BioSystems), RNaseOUT (40 U, Invitrogen), random-hexamer primers (0.04 U, 
Amersham Biosciences), dNTPs (0.5 mmol/L, MBI Fermentas), and supplied optimal 
buffers. The reaction protocol consisted of 3 successive incubation steps at (1) 25°C for 
10 minutes, (2) 37°C for 120 minutes and (3) 85°C for 5 minutes.  
 
 Real-time polymerase chain reaction (PCR) was performed on 1 ng of cDNA 
template containing the appropriate primers (300 nmol/L) and SYBR Green PCR power 
master mix (Applied BioSystems). Primers for each gene were obtained from distinct 
exons that spanned an intron by using the Ensembl Genome Browser program 
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(http://www.ensembl.org) and the UCSC Genome Browser (http://genome.ucsc.edu). The 
sequence specificity of each primer was verified with the Blast program derived from the 
National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov). The 
primers used were as follows: for rat Nestin, Sens 5’-TGCAGGCCACTGATAAGTTC- 
CA-3’ and anti-sense (AS) 5’-TTCTCCTGCTCCAGGGCTTCCA-3’; For rat Collagen 
"1-type III Sens 5’-GGACCTGGTTTCTTCTCACCC-3’ and AS 5’-AGGTAGTTGCA- 
TCCCAATTCA-3’; for rat GAPDH Sens 5’-GGGCTGGCATTGCTCTCA-3’ and AS 
5’-GTCCACCACCCTGTTGCTGTA-3’; for rat TNF-" Sens 5’-GTGATCGGTCCCAA- 
CAAGGA-3’ and AS 5’-GATGAAGAGGGAGCCCATTTG-3’; for rat Il-1! Sens 5’-
TTCAAGGATGAGGACCCAAG-3’ and AS 5’-CATCCCACGAGTCACAGAGGA-3’; 
for rat 18S Sens 5’-AACGGCTACCACATCCAAGG-3’ and AS 5’-GGGAGTGGGTA- 
ATTTGCGC-3’; for rat collagen "1-type I Sens- 5’CTGACGCATGGCCAAGAAGA- 
CA-3’ and AS 5’-CGTGCCATTGTGGCAGATACAGAT; for rat CTGF Sens 5’-AGG- 
CCCTGTGAAGCTGACCTAGA-3’ and AS 5’-TTTTAGGCGTCCGGATGCACT-3’; 
for rat TGF-!III Sens 5’-GCAAGAATCTGCCCCACGAGA-3’ and AS 5’-GACA- 
TGGACAGTGGATGCTGAT-3’; for rat ANF Sens 5’-AGAGCGGACTAGGCTGC- 
AACA-3’ and AS 5’-ATTTGGCTGTTATCTTCGGTA-3’; for rat Serca-2 Sens 5-AGT-
CCCCGTATCCGATGACA-3’ and AS 5’-CATCCTCAGCAGGGACTGGT-3’; for rat 
MCP-1 Sens 5’-TCACCAGCAGCAGGTGTCC-3’ and AS 5’-CACAGATCTCTCTCT- 
TGAGCTTGG-3’. Appropriate negative controls were used for each experiment.  
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Statistics 
 
 Data were presented as means +/- S.E.M., where (n) represents the number of rats 
used in each experiment. Hemodynamic results, protein and mRNA expression were 
evaluated with a 1-way ANOVA and a significant difference was detected using the 
Tukey-Kramer post-hoc test. A value of P < 0.05 is considered statistically significant.  
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Results 
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Nestin expression in infarcted rat hearts 
treated with Dexamethasone 
 
Work from our lab has reported that nestin expression in cardiac resident neural 
stem cells residing in the non-infarcted left ventricle was significantly increased during 
the acute phase of scar formation and healing following myocardial infarction in the 
rat(22). Despite these data, the biological stimuli implicated in the upregulation of nestin 
in cardiac resident neural stem cells in the infarcted heart remains undefined. Numerous 
studies have reported that inflammation plays an integral role in facilitating proper scar 
formation and healing following ischemic damage. Consistent with the latter statement, 
previous work from our lab reported that treatment of myocardial infarcted rats with the 
corticosteroid dexamethasone (0.1mg/kg) led to impaired scar healing and worsening of 
contractile function(42). Based on these data, we performed a preliminary study to assess 
whether dexamethasone treatment could likewise inhibit the upregulation of nestin in 
cardiac resident neural stem cells following myocardial infarction (MI). In 1-week 
myocardial infarcted (MI) rats, nestin protein expression (normalized to GAPDH) was 
increased in the non-infarcted left ventricle (sham=0.49±0.065 versus MI=1.1±0.065; 
n=4 for each group; p<0.01 versus sham) (Figure 1, Table 1). The administration of 
dexamethasone (DEX; 0.1mg/kg) 24 hrs after MI and continued for 6 days suppressed the 
increased nestin protein expression in the non-infarcted left ventricle 
(MI+DEX=0.46±0.057; n=4; p<0.01 versus MI) (Figure 1, Table 1). These findings 
suggest that globally attenuating the inflammatory response with dexamethasone during 
the acute phase of scar formation and healing suppressed the upregulation of nestin in 
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cardiac resident neural stem cells. However, because of the non-selective action of 
dexamethasone, the inflammatory cytokines implicated in the upregulation of nestin in 
cardiac resident neural stem cells following MI remains unknown. Therefore, we 
performed additional experiments and procured the drug XOMA52 that selectively 
targets the action of the inflammatory peptide IL-1! to assess the role of this specific 
cytokine on nestin expression in cardiac resident neural stem cells post-MI.  
 
Figure 1:  
 
 
 
 
 
 
 
 
 
Figure 1. Western Blot of Nestin Protein in the left ventricle of Sham rats and non-
infarcted left ventricle of MI Rats treated with 0.1mg/kg of Dexamethasone. Selected 
Sample of western blot (n = 4), 2 lanes are shown. Nestin protein levels were normalized 
to GAPDH protein content. In the MI rats, a significant increase in comparison to sham 
rats was observed. This increase was abolished by dexamethasone treatment (see table 1 
below). Nestin protein levels were normalized to GAPDH protein content. 
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Table 1 . Non infarcted Left Ventricular Nestin Protein levels of 
sham and MI rats treated with 0.1 mg/kg Dexamethasone 
  
 Nestin 
 
Sham (n=4) 0.484 ± 0.091 
 
MI (n=4) 1.090 ± 0.138* 
 
MI+Dex (n=4) 0.456 ± 0.116** 
 
MI indicates myocardial infarction. Data are presented as mean ± S.E.M normalized 
to GAPDH. Analyzed by an ANOVA followed by a Student-Newman-Keuls  
Multiple test, (*) represents p<0.01 vs Sham; (**) represents p<0.001 vs MI and  
(n) number of rats examined 
 
 
Effect on Cardiovascular function of MI Rat 
hearts treated with Xoma 052  
 
 
Body and heart weights and ventricular function 
of sham and MI rats treated with IgG or XOMA 
052  
 
 To assess the effect of IL-1 on cardiovascular function, several key measurments 
were compared following Xoma 052 treatment. The body weights of IgG-treated sham 
and 3-week IgG-treated MI rats were not different and no significant difference was 
observed in ventricular weight (Tables 2 & 4). Complete coronary artery ligation of the 
heart of adult male Sprague-Dawley rats treated with 0.1 or 1 mg/kg of IgG led to scar 
formation and associated with a concomitant reduction of mean arterial pressure, left 
ventricular systolic pressure, left ventricular rate of contraction and relaxation and 
elevated left ventricular end-diastolic pressure, as compared to IgG-treated sham rats 
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(Tables 3 & 5). Echocardiographic  measurements at 24 hrs post-MI and 2 weeks after 
coronary artery ligation likewise revealed left ventricular systolic (left ventricular systolic 
dimension, LVDs; left ventricular fractional shortening, LVFS; fractional area 
shortening, FAC; left ventricular posterior wall velocity, LVPWV) and diastolic 
dysfunction (E Velocity, indirect measure of stiffness) of IgG-treated MI rats as compared 
to IgG-treated sham rats (Table 6). 
 The body and heart weights of sham rats treated with 0.1 or 1 mg/kg of Xoma 052 
were similar to IgG-treated sham rats (Tables 2 & 4). Furthermore, left ventricular 
systolic and diastolic function measured by a Millar catheter or via echocardiography 
were similar in IgG- and XOMA52-treated sham rats, regardless of the dose injected 
(Table 6). The 0.1 and 1 mg/kg treated sham rats were associated with a modest decrease 
of mean arterial pressure and left ventricular systolic pressure compared to IgG-treated 
rats, but did not reach statistical significance inferior to p<0.05 (Table 3 & 5). Twenty-
four hours after complete coronary artery ligation, 0.1 and 1mg/kg XOMA52 was 
administered to MI rats and 3 weeks later, infarct weight and surface area were similar to 
IgG-treated MI rats (Tables 2 & 4). These data were confirmed by echocardiography, as 
wall motion score index (WMSI), an indirect index of infarct size, was identical in IgG-
treated and Xoma 052-treated MI rats (Table 6). Furthermore, left ventricular systolic 
and diastolic function measured by Millar were not different between Xoma 052- and 
IgG-treated MI rats, regardless of the dose (Tables 2 & 4). However, in the 1 mg/kg 
XOMA52 treated MI rats, a modest improvement of mean arterial pressure and left 
ventricular systolic pressure were observed as compared to IgG-treated MI rats, but did 
not reach statistical significance (Tables 2 & 4). Likewise, in the majority of 
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echocardiographic indices examined, left ventricular systolic and diastolic dysfunction 
reported in IgG-treated MI rats was not improved with XOMA 052 treatment, regardless 
of the dose (Table 6). However, a modest significant improvement of left ventricular 
posterior wall velocity, (LVPWV) was detected in 1mg/kg XOMA52-treated rats as 
compared to IgG-treated rats (Table 6).  
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Table 2.  Body and heart weights of sham and MI rats treated with 0.1 mg/kg of IgG  
         or 0.1 mg/kg XOMA 052 
 
 
 
 
 
 
 
 
 
 
 
 
MI indicates myocardial infarcted rats; BW, body weight; LV, left ventricle and RV, right ventricle.  Data are 
presented as mean±S.E.M, analyzed by an ANOVA followed by a Student-Newman-Keuls Multiple test, and (n) 
number of rats examined.  Note that both sham and MI control rats were treated with the IgG to account for any 
effect of the vector on experimental data.   
 BW  
(gram) 
LV  
(gram) 
LV/BW 
(*1000) 
RV 
 (gram) 
RV/BW 
(*1000) 
Septum  
(gram) 
Septum/
BW 
(*1000) 
Sham+IgG  
(n=9) 
424±6 0.544±0.02 1.29±0.04 0.25±0.006 0.59±0.01 0.26±0.008 0.61±0.02 
MI+IgG 
(n=9) 
421±10 0.443±0.02 1.05±0.05 0.24±0.01 0.64±0.06 0.24±0.01 0.66±0.03 
Sham+XOMA  
(n=9) 
423±10 0.540±0.01 1.28±0.02 0.27±0.02 0.52±0.01 0.28±0.004 0.56±0.02 
MI+XOMA  
(n=9) 
421±11 0.42±0.03 0.98±0.06 0.28±0.008 0.66±0.03 0.30±0.006 0.71±0.03 
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Table 3. Hemodynamic Data of sham and MI rats treated with 0.1 mg/kg of IgG or  
0.1 mg/kg  XOMA 052 
 MAP 
 
(mmHg) 
LVSP 
 
(mmHg) 
LVEDP 
(mmHg) 
LV+dP/dt 
(mmHg/sec) 
LV-dP/dt 
(mmHg/sec) 
Scar Weight 
(grams) 
Scar Surface 
Area  
(cm2) 
Sham+IgG 
(n=8) 
130±4 164±5 6±2 7059±141 6178±163   
MI+IgG(n=7) 110±5a 136±8a 20±5a  5647±274a 4092±136a 0.063±0.009 0.065±0.07 
Sham+XOMA52 
(n=9) 
117±5 153±5 9±2 6779±149 5858±136   
MI+XOMA52 
(n=6) 
113±5 144±5 18±3b 5659±160b 4046±146b 0.069±0.010 0.061±0.04 
 MI indicates myocardial infarcted rats; MAP, mean arterial pressure; LVSP, left ventricular systolic pressure; LVEDP, 
left ventricular end-diastolic pressure; +dP/dt, left ventricular rate of contraction; -dP/dt, left ventricular rate of 
relaxation.  Data are presented as mean±S.E.M, analyzed by an ANOVA followed by a Tukey-Kramer post-hoc test, (a) 
represents p<0.05 versus sham+IgG, (b) represents versus sham+IgG and sham+XOMA52, and (n) number of rats 
examined.  Note that both sham and MI control rats were treated with the IgG to account for any effect of the vector on 
experimental data.   
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Table 4.  Body and heart weights of sham and MI rats treated with 1mg/kg of control 
                IgG or 1   mg/kg Xoma 052 
 
MI indicates myocardial infarcted rats; BW, body weight; LV, left ventricle and RV, right ventricle.  Data are presented as mean ± 
S.E.M, analyzed by a ANOVA followed by a Student-Newman-Keuls Multiple test and (n) number of rats examined. Note that both 
sham and MI control rats were treated with the IgG to account for any effect of the vector on experimental data. 
  
 BW  
(gram) 
      LV  
(gram) 
LV/BW 
(*1000) 
RV 
 (gram) 
RV/BW 
(*1000) 
Septum  
(gram) 
Septum/BW 
(*1000) 
Sham+IgG  (n=9)          447±8 0.592±0.06 1.32±0.04 0.24±0.03 0.53±0.02 0.24±0.007 0.53±0.02 
MI+IgG       (n=8) 444±14 0.539±0.04 1.21±0.07 0.24±0.01 0.60±0.02 0.24±0.01 0.60±0.02 
   Sham+XOMA (n=8) 438±14 0.596±0.05 1.36±0.05 0.27±0.02 0.60±0.05 0.27±0.01 0.61±0.02 
MI+XOMA52 (n=11) 427±8 0.514±0.03 1.20±0.07 0.26±0.01 0.60±0.04 0.28±0.01 0.65±0.02 
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Table 5.  Hemodynamic Data of sham and MI rats treated with 1 mg/kg of IgG or 1 mg/kg Xoma       
052 
 MAP 
 
(mmHg) 
LVSP 
 
(mmHg) 
LVEDP 
(mmHg) 
LV+dP/dt 
(mmHg/sec) 
LV-dP/dt 
(mmHg/sec) 
Scar Weight 
(grams) 
Scar Surface Area  
            (cm2) 
Sham+IgG (n=9) 122±4 159±6 9±1 7104±142 5959±146   
MI+IgG(n=8) 100±5a 126±8a 13±4 5473±245a 3992±214a 0.066±0.008 0.62±0.09 
Sham+XOMA52 (n=8) 110±5 136±6a 11±2 6379±146 5255±151   
MI+XOMA52 (n=11) 109±4 137±5 15±3 5712±223b 4148±209b 0.063±0.009 0.57±0.07 
MI indicates myocardial infarcted rats; MAP, mean arterial pressure; LVSP, left ventricular systolic pressure; LVEDP, left 
ventricular end-diastolic pressure; +dP/dt, left ventricular rate of contraction; -dP/dt, left ventricular rate of relaxation.  Data are 
presented as mean±S.E.M, analyzed by a ANOVA followed by a Student-Newman-Keuls Multiple test, (a) represents p<0.05 
versus sham+IgG, (b) represents versus sham+IgG and sham+XOMA52, and (n) number of rats examined. Note that both sham 
and MI control rats were treated with the IgG to account for any effect of the vector on experimental data
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Table 6. Echocardiographic Measurements of sham and MI rats treated 
with 1 mg/kg of IgG or 1 mg/kg Xoma 052 
 
 
MI indicates myocardial infarction. , analyzed by a ANOVA followed by a Student-Newman Keuls Multiple test,   
represents p<0.05 vs Sham rats; †: vs 24H MI rats and ! MI+1 mg XOMA52 versus MI+IgG. Note that both sham 
and MI control rats were treated with the IgG to account for any effect of the vector on experimental data. 
Sham MI 
 1 mg 0.1 mg 1 mg 0.1 mg 
 IgG 
(n=9) 
Xoma 
(n=8) 
IgG 
(n=8) 
Xoma 
(n=8) 
IgG 
(n=8) 
Xoma 
(n=11) 
IgG 
(n=9) 
Xoma 
(n=9) 
LVDd (mm)  
24 H 
 
7.8±0.5 7.5±0.7 7.0±0.4 7.3±0.7 7.6±0.8 7.8±0.7 7.6±0.6 7.9±0.6 
2-weeks 8.2±0.5 8.1±0.4 8.0±0.4 7.9±0.4 9.9±1.1* 9.8±0.8* 10.0±0.6* 9.8±0.5* 
LVDs (mm)  
24 H 
 
4.0±0.5 3.8±0.8 3.9±0.5 3.8±0.6 5.8±1.2* 6.0±1.0* 5.6±0.8* 5.8±1.1* 
2-weeks 4.0±0.6 3.9±0.5 4.1±0.5 4.0±0.5 7.6±1.8*† 7.1±1.2*† 7.9±0.8*† 7.7±0.8*† 
LVFS (%)  
24 H 
 
49±7 49±11 44±7* 48±5* 24±7* 24±9* 27±8* 26±10* 
2-weeks 51±5 52±5 49±6 49±6 24±11* 27±8* 21±5* 22±6* 
FAC (%)  
24 H 
 
63±9 66±6 57±5 57±5 37±13* 35±11* 34±8* 35±8* 
2-weeks 64±5 65±8 63±5 60±4 36±12* 40±9* 33±4* 34±9* 
WMSI  
24 H 
 
1.0±0.1 1.0±0.1 1.0±0.0 1.0±0.0 1.9±0.4* 1.8±0.4* 1.9±0.3* 1.9±0.3* 
2-weeks 1.0±0.0 1.0±0.0 1.0±0.0 1.0±0.0 1.8±0.3* 1.6±0.2* 1.9±0.2* 1.9±0.3* 
LVPWV 
(cm/s) 
 
24 H 
 
3.8±1.0 3.9±0.9 3.8±0.6 3.9±0.4 2.0±0.6* 2.4±0.7* 2.7±0.6* 2.8±1.0* 
2-weeks 4.5±1.0 4.3±0.6 4.5±0.8 4.2±0.9 2.1±0.9* 2.9±0.7*†! 3.1±0.5* 3.6±0.44* 
E Velocity 
(cm/s) 
 
24 H 
 
111±20 105±14 111±17 103±11 112±11 115±15 114±13 101±16 
2-weeks 111±9 113±13 110±7 105±14 132±19*+ 124±19 134±24*+ 131±21*+ 
 42 
 
Protein Expression and mRNA expression in MI 
rat hearts treated with Xoma 052 
 
 In the non-infarcted left ventricle of IgG-treated MI rats, nestin protein expression 
was increased whereas SERCA2 mRNA levels were significantly reduced (Figure 3; 
Table 7). ANP mRNA levels were also markedly elevated in the non-infarcted left 
ventricle of IgG-treated MI rats, but was not statistically significant (Table 7). SERCA2 
and ANP mRNA levels were measured to assess the effect of Xoma 052 on the 
hypertrophic response.  In 1mg/kg XOMA 052-treated MI rats, nestin protein expression, 
ANP and SERCA2 mRNA levels were similar to IgG-treated MI rats (Figure 3 & Table 
7, 8). In the non-infarcted left ventricle of IgG-treated MI rats, Bax and Bcl-2 protein 
levels were increased, MnSOD protein expression was reduced and eNOS protein content 
unchanged as compared to IgG-treated sham rats (Figure 2 & Table 8). In 1mg/kg 
XOMA 052-treated MI rats, elevated Bcl-2 protein expression persisted and MnSOD 
protein expression remained significantly reduced, as compared to IgG-treated MI rats 
(Figure 2 & Table 8). By contrast, a modest non-significant decrease of Bax protein 
levels was observed in XOMA 052-treated MI rats (Figure 2 & Table 8). Further 
analysis of the latter data revealed that Bax protein expression was markedly reduced in 3 
of 4 MI rats treated with XOMA 052 (Figure 2).   
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Figure 2. Remodelling of the non-infarcted left ventricle of 
MI rats treated with 1 mg/kg of IgG or XOMA52
 
Figure 2. Sample of Western Blot Protein expression of Bax, Bcl-2, MnSOD, eNOS in 
the non-infarcted left ventricle of MI rats treated with 1mg/kg of IgG or Xoma 052 (n=4-
6). No changes were observed in the protein expression of the Bax, Bcl-2, MnSOD, 
eNOS proteins in Xoma-treated samples vs IgG-treated Samples. Overall a non-
signficiant decrease in Bax expression was observed in Xoma-treated MI vs IgG-treated 
MI though there was a strong variability in expression with different animals (see 
discussion below). Protein levels were normalized to GAPDH protein content. 
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Figure 3 :  Nestin protein expression in NILV of 1 mg/kg  
Xoma 052 treatedSham and MI rats 
 
Figure 3. Sample of Western Blot Protein expression of Nestin Expression in the non-
infarcted left ventricle of MI rats treated with 1mg/kg of IgG or Xoma 052 (n=4-6). A 
significant increase in nestin expression was observed in the IgG-MI vs IgG-Sham 
animals. Xoma treatment failed to abolish this increase at a dose of 1mg/kg. Protein 
levels were normalized to GAPDH protein content. 
 
Table 7. Left ventricular ANP and SERCA2 mRNA levels of sham 
and MI rats treated with 1 mg/kg of IgG or XOMA 052 
 
   
 ANP  
 
SERCA2 
Sham +IgG (n=4) 0.83±0.10 
 
0.84±0.08 
MI+ IgG  (n=5) 10±6 
 
0.49±0.04a 
XOMA52+Sham (n=4-6) 0.72±0.30 0.77±0.09 
XOMA52+MI (n=4-6) 9±4 
 
0.54±0.06a 
MI indicates myocardial infarcted rats; ANP, atrial natriuretic peptide and 
SERCA2, sarcoplasmic reticulum Ca2+-ATPase. Note that a strong variability in 
both IgG and Xoma052-treated samples prevents any changes to be statistically 
significant for ANP mRNA expression. Data are presented as mean±S.E.M, 
normalized to !-actin mRNA, analyzed by a ANOVA followed by a Student-
Newman-Keuls Multiple test, (a) represents p<0.05 versus sham+IgG, and (n) 
number of rats examined. Nestin mRNA levels are not displayed because 
changes in protein expression following infarct are regulated primarly 
through post-translational mechanisms.  
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Table 8. Western blot data of sham and MI rats treated with 1 
mg/kg of IgG or XOMA 052  
 
     
 Bcl-2 Bax Mn-SOD eNOS Nestin 
 
Sham +IgG 
(n=4-6) 
0.24±0.07 0.28±0.07 0.89±0.05 0.74±0.05    0.23±0.03 
 
MI+ IgG  
(n=4-6) 
0.51±0.06b 0.75±0.09b 0.57±0.07a 0.81±0.04 0.56±0.05a 
XOMA52+Sham 
(n=4-6) 
0.28±0.05 0.28±0.07 0.66±0.03a 0.75±0.05 0.37±0.04 
XOMA52+MI 
(n=4-6) 
0.58±0.11b 0.59±0.17 0.60±0.05a 0.84±0.19 0.78±0.12b  
MI indicates myocardial infarcted rats; Mn-SOD, Mn-superoxide dismutase and eNOS, 
endothelial nitric oxide synthase. Data are presented as mean±S.E.M, normalized to 
GAPDH protein expression, analyzed by a ANOVA followed by a Student-Newman-
Keuls Multiple test, (a) represents p<0.05 versus sham+IgG, (b) represents versus 
sham+IgG and sham+XOMA52, (*) represents p<0.01 vs MI+IgG and (n) number of 
rats examined. 
 
 
Infarct remodeling of MI rats treated with 1 
mg/kg of XOMA 052  
 
 In order to investigate the effect of Il-1! inhibition on infarct remodelling, a 
variety of factors were investigated. As previously reported, infarct weight, infarct 
surface area and wall motion score index were similar between IgG-treated MI rats and 
XOMA 052-treated MI rats, regardless of the dose (Tables 2, 4, & 6). Consistent with 
these data, mRNA expression of collagen "1, collagen "3, CTGF, TGF-!1 and TGF-!3 in 
the infarct region of XOMA 052-treated MI rats were identical to that observed in the 
infarct region of IgG-treated MI rats (Table 9). 
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Table 9. mRNA levels of the infarct region of sham and MI rats 
treated with 1 mg/kg of IgG or XOMA 052 
 
      
 Collagen "1  
 
Collagen 
"3 
CTGF TGF-!1 TGF-!3 
MI+ IgG  
(n=5) 
1.43±0.07 0.61±0.03 1.71±0.15 0.50±0.03 1.36±0.10 
XOMA52+MI 
(n=5) 
1.26±0.07 0.61±0.02 1.47±0.09 0.66±0.02 1.10±0.08 
MI indicates myocardial infarcted rats; CTGF, connective tissue growth factor, and TGF-
!, transforming growth factor-!. Data are presented as mean±S.E.M, normalized to !-actin 
mRNA, analyzed by a ANOVA followed by a Student-Newman-Keuls Multiple test. (n) 
number of rats examined  
 
 
 
Effect of Xoma 052 on LPS challenged Rats 
 
Effect of LPS administration on the rat heart 
 
The administration of LPS (10mg/kg) to normal rats led to a non-significant loss of 
body weight and a high mortality rate (63.6%) 12-16 hrs after injection (Table 10 & 11). 
LPS was administered in order to initiate a massive inflammatory response in the animal. 
The surviving LPS-challenged rats were associated with a significant increase of heart 
rate, reduced mean arterial pressure and left ventricular contractile dysfunction (Table 
11). The heart of LPS-challenged rats was associated with an inflammatory response as 
the mRNA expression of IL-1", TNF-" and MCP-1 were significantly increased 
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(Figures 5,6 & 7) Nestin protein expression was significantly increased in the heart of 
LPS-challenged rats as compared to sham rats(Table12; Figures 8 & 9), albeit nestin 
mRNA levels were similar between groups (Figure 4)  
 
LPS rats treated with 1mg/kg of Xoma 052 
 
The administration of 1 mg/kg of XOMA 052 8 hrs prior to LPS injection failed to 
significantly reduce the mortality rate (50% vs. 36% survival). However, in the surviving 
LPS-challenged rats, 1 mg/kg of XOMA 052 significantly lowered the increased heart 
rate (table 11). Furthermore, in the surviving LPS-challenged rats treated with 1 mg/kg 
of XOMA 052, a modest improvement of mean arterial pressure and left ventricular 
contractility was observed but did not reach statistical significance (table 11). The 
contractile function of XOMA 052-treated LPS-challenged rat remained significantly 
lower that sham rats (table 11). The increased cardiac expression of Il-1#, TNF-" and 
MCP-1 mRNAs in LPS-challenged rats was not suppressed by the prior administration of 
1 mg/kg of XOMA 052 (Figures 5,6 & 7) Likewise, the increased protein expression of 
nestin in the heart of LPS-challenged rats was not significantly attenuated by 1 mg/kg of 
XOMA 052 (Table 12; Figures 8 & 9).  
 
LPS rats treated with 10mg/kg of Xoma 052  
 
The administration of 10 mg/kg of XOMA 052 8 hrs prior to LPS injection likewise 
failed to significantly reduce the mortality rate (45% vs. 36% survival). However, in the 
surviving LPS-challenged rats, 10 mg/kg of XOMA52 significantly lowered the 
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increased heart rate (table 11) In the surviving LPS-challenged rats treated with 10 
mg/kg of XOMA52, a modest improvement of mean arterial pressure and left ventricular 
contractility was observed but did not reach statistical significance (table 11) Moreover, 
contractile function of XOMA 052-treated LPS-challenged rat remained significantly 
lower that sham rats as observed in LV dp/dT+ and LV dp/dT- indices (table 11). Despite 
the modest effect on contractile function, the administration of 10 mg/kg of XOMA 052 
to LPS-challenged rats significantly attenuated the increased cardiac expression of Il-1# 
and TNF-" mRNAs whereas MCP-1 mRNA levels remained elevated (Figures 5,6 & 7). 
Likewise, the increased protein expression of nestin in the heart of LPS-challenged rats 
was significantly reduced with 10 mg/kg of XOMA 052 (Table 12; Figures 8 & 9).   
 
 
Table 10. Survival of Sham and LPS Challenged Rats  
                 treated with 1-10mg/kg Xoma 052 
 
 Survival 
(%) 
Sham 
(n=4) 
100 
LPS (10mg/kg) 
(n=11) 
36.4 
LPS + Xoma 052 1mg/kg 
(n=10) 
50 
LPS  + Xoma 052 10mg/kg 
(n=11) 
45.5 
(n) number of rats examined  
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Table 11. Body Weight and Hemodynamic data of Sham and LPS 
challenged rats treated with either 0.1mg/kg or 1mg/kg 
of Xoma 052 
 
 Sham 
 
(n=4) 
LPS 
10mg/kg 
(n=3) 
LPS + Xoma 
1mg/kg 
(n=5) 
LPS + Xoma 
10mg/kg 
(n=4) 
Weight (g) 
 
372.0±11.8 362.0±8.3 352.2±5.4 350.3±26.4 
HR 
 
271.3±10.8 366.3±8.7** 303.2±11.8* 
 
320.0±5.0 
Systolic 
Pressure 
 
131.0±6.8 
 
91.1±2.8** 107.0±8.3 96.6±5.6 
Diastolic 
Pressure 
 
101.8±4.3 62.0±3.1** 80.8±6.3 73.4±6.4 
MAP 
 
111.6±5.1 71.7±3.0** 89.6±6.9 81.1±6.0 
LV dP/dT+ 
(mmHg/s) 
6912.8±224.3 5726.8±737.6** 5580.3±592.8 5053.6±763.4 
LV dP/dT- 
(mmHg/s) 
-5409.9±192.6 -4396.4±353.3** -4546.6±576.1 -4327.1±555.9 
HR indicates heart rate; MAP, Mean Arterial Pressure; LV, Left Ventricle. Data are 
presented as mean ± S.E.M. Analyzed by a ANOVA followed by a Student-Newman-
Keuls Multiple test. (*) represents p<0.01 vs LPS. (**) represents p<0.001 vs Sham.(n) 
number of rats examined.  
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Figure 4. Nestin mRNA expression in the LV of rat heart 
following administration of LPS (10mg/kg) and Xoma 052 
treatment. 
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 Data are presented as mean±S.E.M, normalized to 18S RNA expression, analyzed by a 
ANOVA followed by a Student-Newman-Keuls Multiple test. (n=4-6) number of rats 
examined. Results were normalized to 18S mRNA transcript levels.  
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Figure 5. IL-1! mRNA expression in the LV of rat heart following 
administration of LPS (10mg/kg) and Xoma 052 
treatment 
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Data are presented as mean±S.E.M,   normalized to 18S RNA expression, analyzed by a 
ANOVA followed by a Student-Newman-Keuls Multiple test. (*) represents p<0.05 vs 
LPS. (n=4-6) number of rats examined. Not shown on graph: p<0.001 LPS vs Sham. 
Results were normalized to 18S mRNA transcript levels. 
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Figure 6. TNF-" mRNA expression in the LV of rat heart 
following administration of LPS (10mg/kg) and Xoma 
052 treatment 
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 Data are presented as mean±S.E.M, normalized to 18S RNA expression, analyzed by a 
ANOVA followed by a Student-Newman-Keuls Multiple test. (*) represents p<0.001 vs 
LPS. (n=4-6) number of rats examined. Not shown on graph: p<0.001 LPS vs Sham. 
Results were normalized to 18S mRNA transcript levels. 
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Figure 7. MCP-1 mRNA expression in the LV of rat heart 
following administration of LPS (10mg/kg) and Xoma 
052 treatment 
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Data are presented as mean±S.E.M, normalized to 18S RNA expression, analyzed by a 
ANOVA followed by a Student-Newman-Keuls Multiple test. (n=4-6) number of rats 
examined. Results were normalized to 18S mRNA transcript levels. Not shown on 
graph: p<0.001 LPS vs Sham. A strong variability resulting in a high S.E.M. for 1mg/kg 
Xoma-treated LPS samples prevented any changes from being significant.  
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Figure 8. Western Blot of Nestin Protein expression in LV of Sham 
and LPS-Challenged Rats treated with Xoma 052. 
 
 
 
Table 12. Nestin protein expression from the left ventricle of sham 
and LPS-challenged rats treated with 1 and 10 mg/kg of 
XOMA 052 
 
 Nestin 
Sham (n=4-6) 0.203±0.068 
LPS 10mg/kg (n=4-6) 0.8933±0.291 
LPS + Xoma052 1mg/kg (n=4-6) 0.685±0.323 
LPS + Xoma052 10mg/kg (n=4-6) 0.315±0.088* 
 
LV indicates the left ventricle of the rat heart; LPS indicates Lipopolysaccharide. Data are 
presented as mean±S.E.M, normalized to GAPDH protein expression, analyzed by a 
ANOVA followed by a Student-Newman-Keuls Multiple test. (*) represents p<0.01 vs LPS 
treated rats. (n) number of rats examined. Note that a strong variation in nestin 
expression was observed in animals treated with 1mg/kg Xoma 052 thereby explaining 
any discrepancies  between figure 8 and final compilated results from all animals 
displayed in table shown above. 
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Figure 9. Nestin Protein expression in the LV of rat heart 
following administration of LPS (10mg/kg) and Xoma 
052 treatment 
 
 
 
Data are presented as mean±S.E.M, normalized to 18S RNA expression, analyzed by a 
ANOVA followed by a Student-Newman-Keuls Multiple test. (n=4-6) number of rats 
examined. (*) indicates p < 0.01 vs LPS treated rats. Not shown on graph: p<0.001 LPS 
vs Sham. Results were normalized to 18S mRNA transcript levels. 
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Discussion 
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Inhibition of the Inflammatory Response in 
the rat heart following Dexamethasone 
Treatment  
 
 
Consistent with previous work from our lab, nestin protein expression was upregulated in 
neural cardiac stem cells of the non-infarcted left ventricle during the acute phase of scar 
formation and remodeling following myocardial infarction of the rat heart. Interestingly, 
the upregulation of nestin in the non-infarcted left ventricle was almost completely 
abolished following dexamethasone treatment. Dexamethasone is a synthetic 
glucocorticoid with powerful immunosuppressant and anti-inflammatory properties. 
Therefore, our results would suggest that the upregulation of nestin following MI is  
associated with one or several components of the inflammatory pathway. However, these 
data raised many more questions as dexamethasone, as an immunosuppressant, could be 
suppressing the expression of a panel of inflammatory cytokines. Indeed one or several 
inflammatory cytokines, including IL-1!, IL-6 and TNF-", could be responsible for the 
upregulation of nestin(34, 43). Therefore, the identity of the inflammtory cytokine 
potentially implicated in the increased expression of nestin in the non-infarcted left 
ventricle remained unknown. To investigate this further, we acquired the novel antibody 
Xoma 052 which targets IL-1! with high affinity and specificity. Investigating the role of 
IL-1! on nestin expression is an excellent starting point as it is a primary mediator of the 
inflammatory response, itself responsible for the release of a plethora of other 
inflammatory cytokines(34). Furthermore, a study by Liu et al, 2000, reported a decrease 
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in induced levels of IL-1! with dexamethasone treatement prior to heatstroke-induced 
arterial hypotension and ischaemic neuronal damagein rats(44).  
 
 
Effect of Xoma 052 on the infarcted rat heart 
 
In addition, to examining the role of IL-1! on the expression of nestin, a 
secondary study was conducted to investigate the role of this pro-inflammatory cytokine 
on cardiac function during the acute phase of healing following myocardial infarction. In 
this study, we demonstrated that Xoma 052 administration at a dose of 1mg/kg to 
infarcted male Sprague-Dawley rats during the acute phase of scar formation (24 hrs after 
complete coronary artery occlusion) did not lead to infarct expansion or infarct thinning. 
Furthermore, Xoma 052 treatment of MI rats did not further worsen left ventricular 
systolic and diastolic function nor did it inhibit the hypertrophic response of the non-
infarcted left ventricle, measure by ANP and SERCA2 mRNA expression, compared to 
IgG-treated MI rats. However, a modest non-significant improvement of mean arterial 
pressure and left ventricular systolic pressure were observed in MI rats treated with 1 
mg/kg of Xoma 052. Certain cytokines including IL-1! have been shown to have a 
positive chronotropic effect on the spontaneous beating of rat cardiac myocytes(45). It is 
possible that the lowering of mean arterial pressure and left ventricular systolic pressure 
reported in sham rats treated with Xoma 052 may have partially masked the beneficial 
effects of the drug in the treated infarcted rats. If the administration of Xoma 052 
neutralized local concentrations of IL-1!, then this would offer a possible explanation for 
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the observed decrease in mean arterial pressure. Interestingly, a significant improvement 
of left ventricular posterior wall velocity was observed in 1mg/kg Xoma 052-treated rats 
as compared to IgG-treated MI rats. The latter data are in part concordant with the modest 
non-significant improvement of left ventricular systolic pressure observed in MI rats 
treated with 1 mg/kg of Xoma 052.  
 
Influence of Xoma 052 on the apoptotic 
response of the infarcted rat heart 
 
The administration of 1 mg/kg of Xoma 052 to MI rats appeared to reduce the 
expression of the pro-apoptotic protein Bax, whereas no effect was observed on the anti-
apoptotic protein Bcl-2 in the non-infarcted left ventricle. Though we report a modest 
non-significant decrease in the protein Bax, closer examination showed that 75% of 
animals showed a massive decrease in the expression of the protein. We have 
hypothesized that a variety of factors could explain this oddity such as certain animals 
were unresponsive to the antibody treatment, variation in infarct size or inadequate drug 
delivery to the targeted areas. Nonetheless, these data would suggest that Xoma 052 
would appear to target cardiac cell apoptosis and a reduced apoptotic response in the 
infarcted rat heart could plausibly  have contributed in part to improvement in left 
ventricular posterior wall velocity and consequently, the modest improvement of left 
ventricular systolic pressure. This is consitent with previously reported findings that IL-
1! signaling can induce apoptosis mediated in part by the Bax protein(46). 
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Therefore, Xoma 052 administration during the acute phase of scar formation and 
subsequently injected during scar healing did not exert a detrimental effect on infarct 
formation, cardiac hypertrophy, left ventricular systolic or diastolic function. However, 
though we followed the experimental protocole outlined by Xoma, we cannot exclude the 
possibility that the 1mg/kg dose of Xoma 052 was insufficient or that the antibody was 
ineffective in inhibiting the IL-1" signalling pathway following myocardial infarction. It 
is quite possible that with a higher dose, improvements in cardiac function would be 
observed. 
 
Effect of Xoma 052 in LPS treated rats 
 
Influence of the Inflammatory Response on 
cardiac function 
 
To confirm the selectivity of the Xoma 052 antibody, the lipopolysaccharide 
(LPS) model of systemic inflammation was examined. Injecting LPS in normal adult rats 
induced a massive inflammatory response, charcterized by significant increases in mRNA 
trancript levels for many key inflammatory cytokines including IL-1", TNF-# and MCP-
1. As expected, there was a high mortality rate in LPS challenged animals. Sixteen hours 
following LPS injection, we measured a decrease in MAP and a concomitant increase in 
heart rate. These observations are consistent with previously reported studies involving 
LPS administration to rodents. Gardiner et al, 1998 observed similar acute hemodynamic 
changes in rats following LPS injection. Interestingly, they also observed a decrease in 
MAP and an increase in HR following IL-1" administration alone(47). This observation 
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is of little surprise since IL-1" has been shown to be a primary mediator of the 
inflammatory response induced by exposure to LPS. It would therefore be logical to 
assume that IL-1" is, at least partly, responsible for the hemodynamic changes in LPS 
challenged rats. It has been hypothesized that IL-1" induces tachycardia via adrenergic 
stimulation of the nervous system. Indeed, treatment with Atenolol, a "1–adrenergic 
receptor antagonist, prevented IL-1" induced tachycardia in rats(48). However, inhibitors 
of #1-adrenergic receptors, found on blood vessels, failed to prevent an increase in heart 
rate. This would strongly suggest an association between sympathetic nervous system 
activation and increased levels of IL-1". This explanation would be consistent with our 
results as we have shown that treatment of LPS challenged rats with the Xoma 052 
antibody (1mg, 10mg/kg) partially attenuated the increased heart rate although treatment 
had no effect on blood pressure. It would seem that the observed lowering of blood 
pressure is mediated via an IL-1" independent mechanism.  
 
Effect of Xoma 052 on Protein Expression  
It was surprising that few changes in protein expression, with the exception of the 
intermediate filament protein nestin, were observed in Xoma 052 treated LPS challenged 
animals. It is entirely possible that the time between LPS injection and sacrifice (16 hrs) 
was insufficient to upregulate the proteins of interest such as Bcl-2 and Bax. Transcript 
levels of the LV for several key pro-inflammatory cytokines were significantly 
upregulated in LPS challenged rats thereby confirming that a significant acute 
inflammatory response was achieved in the animal. However, no reduction in transcript 
levels were observed in LPS challenged rats treated with a 1mg/kg dose of Xoma 052. 
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Considering a significant block of the transcript levels of IL-1! and TNF-" were 
observed in LPS challenged animals treated with 10mg/kg, this would suggest that the 
drug is effective and that the 1mg/kg dose of Xoma052 is simply insufficient. Indeed, 
inhibition of the IL-1! signaling pathway by the antibody may block further release of Il-
!, which is potentiated by its own autocrine/paracrine stimulation, in addition to 
attenuating TNF-" release, which is mediated in part by IL-! signaling(33). These two 
cytokines are primary mediators of the inflammatory response and a decrease in their 
mRNA levels would suggest a reduced local inflammatory response in these animals. The 
fact that we did not observe a change in the transcript levels of MCP-1 in LPS-rats treated 
with 10mg/kg of Xoma compared to animals treated only with LPS further suggests that 
the changes observed are not due to widespread reduction in cytokine levels but rather 
selective inhibition of the Il-! signaling pathway. 
 
Effect of Xoma 052 on the neural stem cell 
phenotype 
 
As previously reported, dexamethasone mediated suppression of nestin in the 
infarcted rat heart supports a role of the inflammatory response in the upregulation of the 
intermediate filament protein by neural progenitor/stem cells. In this regard, LPS-induced 
inflammation provides an ideal model to examine the effect of Il-1!, via the use of Xoma 
052, to determine its role on nestin expression by cardiac resident neural progenitor/stem 
cells. As observed in the infarcted rat heart, the  upregulation of the intermediate filament 
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protein nestin was observed in the heart of LPS challenged rats, further supporting the 
relation between the upregulation of nestin and the inflammatory response. Once again, 
the administration of 1mg/kg of Xoma 052 prior to LPS challenge failed to significantly 
inhibit the upregulation of nestin in the rat heart. Thus, the 1 mg/kg dose of XOMA52 
was insufficient to inhibit the action of the inflammatory response on nestin expression. 
By contrast, the 10mg/kg dose of Xoma 052 significantly reduced  the upregulation of 
nestin in the heart of LPS challenged rats. Whether the latter effect is secondary to the 
reduction of IL-1! and/or TNF-" remains unknown. It is interesting to note that there 
was no difference in the expression of nestin mRNA in the LV. Transcriptional regulation 
of the nestin protein has been previously reported in both brain and spinal cord 
injuries(49). A plausible explanation for this discrepancy would be that the upregulation 
of nestin in the heart during an inflammatory response is modulated not by transcription 
but via a post-translational mechanism. Indeed, the expression of other intermediate 
filaments has been found to be under the control of the ubiquitin-proteosome 
pathway(50). A study on nestin expression in the kidney by Sakairi et al (2007) reported 
an increase in nestin expression after unilateral ureteral obstruction despite a decrease in 
transcript levels. In the latter study, nestin expression was increased following the 
administration of proteosome inhibitors(50). Though this model is quite different from 
our own, it shows an alternative means for the control of nestin expression. Future studies 
examining the relationship between the inflammatory response and the activity of the 
ubiquitin-proteosome pathway are required in order to identify the exact cellular 
mechanism responsible for the up-regulation of the nestin in the heart.  
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MI vs LPS model Comparison 
An interesting discrepancy in the regulation of nestin expression was observed between 
the LPS and infarct models. The up-regulation of nestin with the Xoma 052 antibody was 
observed in the LPS model but had no observed effect in the infarct model. 
It is possible that more definite conclusions could have been achieved with the infarct 
model, however we were somewhat restricted in our experimental parameters by the 
company funding the project. Indeed, preliminary studies on the Xoma 052 antibody have 
concluded that doses of 0.1mg/kg and 1mg/kg are most effective in rodents. However, 
considering that positive results were observed in the LPS model using a higher dose, it 
may be better for future experiments to utilize a 10mg/kg dose in the infarct model. 
Furthermore, though we were trying to reproduce the clinical setting as close as possible 
in the infarct model, it may also be more effective to administer the Xoma 052 antibody 
prior to coronary artery ligation. Prophylactic use of the antibody might also prove to 
have some clinical applications as a previous study has shown Xoma 052 to be beneficial 
in the treatment of diabetes(51). This would be helpful as diabetics experience a greater 
mortality and morbitity following an ischemic event(52). 
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Conclusion  
 66 
We have found that the administration of 1mg/kg Xoma 052 during the acute phase of 
scar formation failed to curb the upregulation of nestin observed following MI. 
Furthermore, it resulted in only mild improvements in cardiac function while having no 
detrimental effects on scar formation. For the same dose, no improvement was observed 
when the drug was administered prior to LPS injection in rats. Treatment of LPS 
challenged rats with 10mg/kg of Xoma 052 led to a significant reduction in the mRNA 
expression of key inflammatory cytokines. In addition, the expression of nestin was 
significantly reduced, supporting a role of inflammation in the expression of the 
intermediate filament protein in cardiac resident neural progenitor/stem cells. These data 
provide the impetus for future examination of the myocardial infarct model. Firstly, the 
10mg/kg dose should be administered following myocardial infaction to measure its 
effect on neural stem cells and cardiac function. Should this prove inconclusive, further 
experiments can be performed administering the 10mg/kg dose prophylacticly to best 
simulate the conditions of the LPS experiments that showed changes in the levels of 
nestin upregulation. 
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